Mutations in the key rod phototransduction enzyme phosphodiesterase 6 (PDE6) are known to cause recessive retinitis pigmentosa in humans. Mouse models of mutant PDE6 represent a common approach to understanding the mechanisms of visual disorders related to PDE6 defects. Mutation N605S in the PDE6B subunit is linked to atypical retinal degeneration 3 (atrd3) in mice. We examined PDE6 in atrd3 mice and an atrd3 mutant counterpart of human cone PDE6C expressed in rods of transgenic Xenopus laevis. These animal models revealed remarkably different phenotypes. In contrast to dramatic downregulation of the mutant rod PDE6 protein and activity levels in mice, expression and localization of the cone PDE6C in X. laevis were essentially unaffected by this mutation. Examination of the PDE6B mRNA in atrd3 retina showed that the mutation-carrying exon 14 was spliced-out in the majority of the transcript. Thus, retinal degeneration in atrd3 mice is caused by low levels of PDE6 protein due to defective processing of PDE6B pre-mRNA rather than by deleterious effects of the N605S mutation on PDE6 folding, stability or function.
Introduction
Rod and cone photoreceptor cells respond to light stimuli by activating phosphodiesterase-6 (PDE6) that hydrolyze cGMP thereby modulating cGMP-gated channels in the plasma membrane (Burns & Arshavsky, 2005; Fu & Yau, 2007; Lamb & Pugh, 2006) . Rod PDE6 is a heterotetramer composed of two catalytic subunits, PDE6A and PDE6B, and two copies of the small inhibitory Pc subunit. Cone PDE6 is highly homologous to the rod enzyme and is a tetramer comprised of two identical catalytic subunits PDE6C and two copies of a cone-specific Pc subunit (reviewed in Zhang and Cote (2005) ). Mutations in the PDE6A and PDE6B genes are responsible for a significant fraction of cases of recessive retinitis pigmentosa (RP), a common disease of progressive photoreceptor degeneration leading to loss of vision. In addition, mutations in rod PDE6 may lead to a non-progressive night blindness (Dryja et al., 1999; Huang et al., 1995; McLaughlin et al., 1993) . The PDE6B H258N mutation was reported in the Rambusch form of dominant stationary night blindness (Gal et al., 1994) . Recently, PDE6C mutations have been found in human patients with progressive cone dystrophy and achromatopsia (Chang et al., 2009; Thiadens et al., 2009) . These disorders of cone function are characterized by low visual acuity and lack of color discrimination. Certain pathogenic PDE6 alterations such as nonsense mutations, frame-shifts, or splicing defects apparently result in complete loss of PDE6 function. Often PDE6 mutations in RP and achromatopsia are missense mutations leading to substitutions of conserved residues within the regulatory GAF domains or the catalytic domains. The mechanisms of such PDE6 mutations are not understood and may include loss of PDE6 function due to protein folding defects, deficient transport of PDE6 to the site of phototransduction, or abnormal function of the enzyme.
Despite numerous efforts, heterologous expression of PDE6 has not been attained. Thus, characterization of animal models has been the main approach to understanding the mechanisms of human visual disorders caused by mutations of the PDE6 catalytic subunits. Mouse models with spontaneous or chemically-induced mutations in PDE6B and, more recently, PDE6A and PDE6C have been identified (Bowes et al., 1990; Chang et al., 2007 Chang et al., , 2009 Hart et al., 2005; Sakamoto et al., 2009; Pittler & Baehr, 1991; Thaung et al., 2002) . The rd1 mouse is a classical loss-of-function model with disruption of the PDE6B gene causing elevation of cGMP levels and rapid retinal degeneration (Bowes et al., 1990; Farber & Lolley, 1974; Pittler & Baehr, 1991) . Similarly, a spontaneous disruption of the PDE6C gene in the cpfl1 mutant mouse causes rapid degeneration of cones (Chang et al., 2009 missense mutations in rod PDE6 are more representative of the majority of PDE6-related cases of RP. The progression of photoreceptor degeneration in these animal models is slower than in rd1 mice, theoretically allowing examination of biochemical outcomes of PDE6 mutations. Furthermore, a slow progression of retinal degeneration in mutant mice potentially indicates change of function as opposed to loss-of-function mutations. Three recessive PDE6B alleles causing a relatively slow onset of retinal degeneration were originally selected in a screen for novel N-ethyl-N-nitrosourea-induced mutations that lead to vision disorders in the mouse (Hart et al., 2005; Thaung et al., 2002) . The mutant alleles were termed atrd1-atrd3 for atypical retinal degeneration (Thaung et al., 2002) . The atrd3 allele appeared particularly interesting (Barren et al., 2009; Hart et al., 2005) . This allele was originally reported to carry the N606S mutation (Hart et al., 2005) . However, our sequencing of genomic DNA obtained from atrd3 mice indicated a N605S mutation, which is in agreement with the current annotation of the mutant allele at the Mouse Genome Informatics database (ID: MGI: 2178316). The position corresponding to Asn 605 in mouse PDE6B is not absolutely conserved among PDEs. PDE1 and PDE3 contain a Thr residue, whereas PDE4 and PDE10 contain a Ser residue at this position, which is analogous to the Asn ? Ser substitution in atrd3 mice. Moreover, the atomic structure of the chimeric PDE5/PDE6 catalytic domain complexed with the inhibitory peptide of Pc revealed that the Asn residue contributes to the Pc-binding site, suggesting a potential functional defect of the atrd3 mutant (Barren et al., 2009) . To investigate the mechanism of the PDE6B N605S mutation in retinal degeneration, we examined PDE6 in atrd3 mice. In addition, we generated transgenic X. laevis expressing an atrd3 counterpart of EGFP-fused human PDE6C in rods, PDE6C-N610S. Surprisingly, the two animal models revealed strikingly different phenotypes. In mouse atrd3 retina, levels of PDE6B expression and total PDE6 activity were markedly downregulated, whereas in frog retina, expression and localization of EGFP-PDE6C were essentially unaffected by this mutation. The difference in the phenotypes is reconciled by the finding of the abnormal PDE6B pre-mRNA splicing in mutant mice leading to very low expression levels of PDE6.
Methods

Animals
Homozygous atrd3 +/+ female mice were obtained from the Mary Lyon Center (England). The mice were mated with wild-type mice (C57Bl/6) to obtain heterozygous atrd3 +/À mice, which were subsequently bred to obtain homozygous atrd3 +/+ mice. Mice were genotyped by PCR-amplification and DNA sequencing of the mutant PDE6B region. Transgenic X. laevis expressing EGFP-PDE6C in rods were generated by the method of sperm nuclear transplantation as previously described ). The N610S mutation was introduced by PCR-directed mutagenesis into the PDE6C DNA sequence which was then cloned into the pXOP(À508/ +41)EGFP vector using NotI and XmaI sites. The construct sequence was confirmed by automated DNA sequencing. X. laevis tadpoles expressing EGFP-PDE6C-N610S were obtained similarly as described for EGFP-PDE6C ). All experimental procedures involving the use of mice and frogs were carried out in accordance with the protocol approved by the University of Iowa Animal Care and Use Committee.
Immunofluorescence
Mouse eyeballs were enucleated and the corneas were perforated with a 21 gauge needle, fixed in PBS with 4% formaldehyde for 1 h and cut in half. The cornea and lens were removed, and the eyecups were submersed in a 30% sucrose solution in PBS for 5 h at 4°C. The eyecups were then embedded in tissue freezing medium (Triangle Biomedical Sciences) and frozen on dry ice.
Radial sectioning (10 lm) of the retina was performed using a cryomicrotome HM 505E. Retinal cryosections were air-dried and kept at À80°C. The sections were warmed up to room temperature and incubated in PBS/0.1% Triton X-100 for 30 min. Labeling with anti-rhodopsin 1D4 monoclonal antibody (1:200) (Santa Cruz Biotech), rabbit anti-PDE6B PA1-722 (1:1000) (Thermo Scientific) antibody, anti-PDE6 MOE antibody (1:1000) (CytoSignal), or antiPc-(63-87) antibody (1:1000; gift of Dr. R. Cote, University of New Hampshire) was performed in PBS containing 3% BSA for 1-2 h at 25°C. Following 1-h incubation with goat anti-mouse AlexaFluor 488, goat anti-rabbit AlexaFluor 488, or goat anti-rabbit AlexaFluor 568 secondary antibodies (Invitrogen) (1:1000), the sections were visualized using a Zeiss LSM 510 confocal microscope. In situ cell death detection kit, TMR red (Roche), was used for TUNEL staining of retina cryosections according to manufacturer' protocol. The sections were counterstained with To-Pro3 (Invitrogen).
EGFP-fluorescence
At about stage 48-50, retinas from transgenic tadpoles were dissected into small pieces in a Ringer's buffer and the EGFPfluorescence in living photoreceptor cells was imaged using LSM510 (Zeiss).
PDE6 extraction, immunoblotting, immunoprecipitation, and PDE6 activity assays
To determine the total levels of expression of PDE6 subunits, retinas of P10 atrd3 +/+ and wild-type (C57Bl/6) mice were homogenized in 10 mM Tris-HCl buffer pH 7.5 containing 1 mM 2-mercaptoethanol and 1% Triton X-100 (25 ll/retina) and centrifuged at 16,000g for 10 min. The supernatants were separated by SDS PAGE and analyzed by Western blotting with anti-PDE6 antibody 63F (gift of Dr. R. Cote, University of New Hampshire) and anti-PDE6B PA1-722 (Thermo Scientific). For PDE6 activity analyses, P10 atrd3
and WT retinas were homogenized with a pestle in an Eppendorf tube in 20 mM Tris-HCl buffer (pH 7.5) containing 120 mM NaCl, 1 mM MgSO 4 , 1 mM 2-mercaptoethanol, and complete protease inhibitor cocktail (Roche) (30 ll/retina). Aliquots of retina homogenates were used for measurements of the total levels of PDE6 activity following trypsin-treatment (30 lg retina protein/2 lg trypsin, 0-20 min, 0°C, terminated with 10Â SBTI). 5-min treatment maximally activated PDE6 activity. The rest of the homogenates were centrifuged (20,000g, 20 min, 4°C), and the resulting pellet was re-suspended in hypotonic 10 mM Tris-HCl (pH 7.5) buffer (15 or 30 ll/retina) containing 1 mM b-mercaptoethanol and complete protease inhibitor cocktail. The PDE6-containing hypotonic supernatants (70,000g, 60 min, 4°C) were used immediately or stored at À80°C. Samples of PDE6 extracts containing equal amounts of functional PDE6 were used for immunoprecipitation. Hypotonic PDE6 extract from 20 to 25 atrd3 +/+ retinas contained as much functional PDE6 as that from 1 WT retina as determined by PDE6 activity after trypsin-treatment. Dynabeads with Protein G (30 ll, 30 mg/ml) (Invitrogen) were washed with 20 mM Tris-HCl (pH 7.5) buffer containing 500 mM NaCl, 1 mM MgSO4, and 1 mM 2-mercaptoethanol (buffer A) and incubated with anti-PDE6B PA1-722 (5 lg) for 60 min at 25°C. The beads were washed from unbound proteins two times with buffer A, followed by the addition of PDE6 extracts from WT, Nrl À/À or atrd3 +/+ retinas and incubation with rotation for 3 h at 4°C. The beads were then washed four times with buffer A, one time with buffer A minus NaCl, and finally one time with buffer A. Resins with bound proteins after the final wash were re-suspended in 20 mM Tris-HCl (pH 7.5) buffer containing 100 mM NaCl, 10 mM MgSO4, and 1 mM 2-mercaptoethanol and aliquots of suspension (5 ll out total 750 ll) were assayed for PDE activity after activation with trypsin (0.5 lg trypsin, 5 min, 20°C, terminated with 10Â SBTI). Immunoprecipitated proteins from the remaining samples of resin were eluted with SDS-sample buffer and analyzed by Western blotting using the PDE6 MOE antibody (CytoSignal). Immunoblotting of retinal extracts from transgenic EGFP-PDE6C and EGFP-PDE6C-N610S retinas with anti-GFP B-2 monoclonal antibody (Santa Cruz Biotech) and anti-PDE6 MOE antibody (CytoSignal) was performed as previously described (Muradov, Boyd, & Artemyev, 2010; Muradov et al., 2009 ).
RNA isolation and RT-PCR
Total RNA was isolated from six P10 retinas of each C57Bl/6 (WT) and atrd3 mice using the TRI reagent according to Molecular Research Center protocol. RT-PCR amplifications were performed on both RNA samples using SuperScript III One-Step RT-PCR kit (Invitrogen) and three pairs of primers designed to generate overlapping products covering the full-length PDE6B cDNA: 1st pair -(À24)-(À1) and 834-866, 2nd pair -794-823 and 1854-1886, and 3rd pair -1622-1655 and 2575-2606 (3 0 -UTR).
Analysis of PDE6B transcripts by real-time PCR
First-strand cDNAs were synthesized on total RNAs from p10 C57Bl/6 (WT) and atrd3 retinas using PDE6B exon 15-specific primer and SuperScript III Reverse transcriptase (Invitrogen). Four serial dilutions of these cDNA samples (each in triplicate) were used as templates in real time PCR amplifications of $130 bp products from exons 12 and 14 with an Applied Biosystems 7000 Real-Time PCR System and iQ™ SYBR Ò Green Supermix (Bio-Rad) as per the manufacturers' protocols. The total levels of PDE6B transcripts in control and atrd3 samples were normalized using the threshold cycle values (C T ) for the exon 12 PCR product. The level of exon 14 skipping in atrd3 retina was determined based on the C T values for exon 14.
Genomic DNA analysis
Genomic DNAs of WT and atrd3 mice were isolated from mouse tail clips. PCR products from genomic DNA covering PDE6B exons 13-15 and flanking introns were sequenced. No differences except the Asn ? Ser (A to G) mutation in exon 14 were found between the WT and atrd3 samples.
Results
Retinal degeneration in atrd3 mice
To identify an appropriate time point for examination of PDE6 in atrd3 mice we determined the time-course for the onset of retinal degeneration. The TUNEL staining of retina sections from homozygous atrd3 mice indicated that the outer nuclear layer (ONL) of atrd3 +/+ mice is normal at postnatal day 10 (P10), but apoptotic nuclei appear by P14 (Fig. 1) . The photoreceptor cell death led to a twofold reduction in the thickness of ONL by P19, and only two cell layers were left in the ONL by P30 in atrd3 mice (Fig. 1) . Heterozygous atrd3 +/À mice displayed normal retinal morphology with no signs of retinal degeneration ( Fig. 1 ) and served as controls in the immunofluorescence analyses. The immunofluorescence staining of rhodopsin showed that the OS layer is well-defined in both heterozygous and homozygous atrd3 mice at P10. However, OS in homozygous atrd3 mice deteriorated at P19 and disintegrated at P30 (Fig. 2) . Thus, P10 retinas were used in the study to avoid potential influence of apoptosis on PDE6 expression and activity.
Expression and activity of PDE6 in atrd3 retinas
The total levels of expression of PDE6 subunits were probed in P10 retina extracts of atrd3 and control mice using the PDE6 antibody 63F that recognizes rod PDE6AB and cone PDE6C equally well (Muradov, Boyd, & Artemyev, 2010) . Western blotting using this antibody revealed a double band of $88 and 90 kDa corresponding to the wild-type PDE6 in WT (C57Bl/6) retina and only a single 90 kDa band in atrd3 retina (Fig. 3) . The 90 kDa signal in the atrd3 retina was comparable to that in controls. The re-blot analysis with PDE6B-specific antibody PA1-722 (ABR) showed a specific staining of the 88 kDa band in control retina and the absence of the corresponding band in the atrd3 +/+ retina (Fig. 3) . A weak signal seen in Fig. 1 . Time-course of apoptosis in atrd3 +/+ retinas. Retina cryosections from heterozygous atrd3 +/À (control) and homozygous atrd3 +/+ mice were TUNEL-stained (red) using cell death detection kit TMR red (Roche), and counterstained with To-Pro3 (blue). Scale bar -10 lm.
the atrd3 sample is also present in the control sample just above the PDE6B band. This signal is apparently not PDE6B-specific. Thus, the protein level of PDE6B is markedly reduced, whereas the level of PDE6A is seemingly unchanged in atrd3 +/+ retina. The 90 kDa band may include PDE6C since it cannot be distinguished from PDE6A with the 63F antibody. Immunoblotting of control and atrd3 +/+ retinal extracts with Pc-specific antibody showed that Pc is also markedly reduced in the mutant retina (Fig. 3) . In agreement with the immunoblotting results, immunofluorescence analysis using the PDE6B antibody PA1-722 showed robust staining of OS layer of P10-P30 control retina sections but no PDE6B staining using atrd3 +/+ retina sections (Fig. 4) . Antibody 63F is not suitable for immunofluorescence analysis. However, MOE antibody that recognizes both PDE6A and PDE6B did reveal the presence of greatly diminished levels of PDE6, presumably PDE6A, in the photoreceptor layer of atrd3 +/+ retina (Fig. 5A) . A fraction of PDE6 appears to be mislocalized to the rod inner compartments. The PDE6A immunofluorescence signal in atrd3 +/+ retina is weaker than expected based on the PDE6A level detected by antibody 63F (Fig. 3) . This may be due to misfolding of PDE6A. Immunofluorescence analysis using Pc-specific antibody revealed Pc-staining in the ROS layer of control P10 retina and no Pc-signal in the P10 atrd3 +/+ retina, confirming a dramatic reduction in the level of the inhibitory subunit (Fig. 5B) . The total levels of PDE6 activity were measured in P10 retina homogenates following trypsin treatment. Trypsin fully activates PDE6 catalytic subunits by removing the inhibitory Pc subunits, and the trypsin-activated PDE6 activity is a good measure of total functional PDE6. The PDE assays demonstrated that PDE6 activity is reduced by $18-fold in atrd3 +/+ retinas (0.060 ± 0.005 nmol cGMP/lg protein/min) compared to control retinas (1.1 ± 0.1 nmol cGMP/lg protein/min). The dramatic reduction in total PDE6 activity raises the question of what fraction of the residual PDE6 activity can be attributed to cone PDE6C. To address this question, we performed immunoprecipitations of PDE6 from WT (C57Bl/6) and atrd3 +/+ retinas using PDE6B PA1-722 antibody. Control immunoprecipitations were also carried out using Nrl À/À retina extracts. Nrl À/À retinas predominantly express cone PDE6C as well as trace amounts of rod PDE6AB (Kolandaivelu, Chang, & Ramamurthy, 2011) . The inputs into IP experiments were equalized by PDE6 activity determined in aliquots after activation with trypsin. Thus, the inputs contained equal amounts of combined functional PDE6 from both rods and cones. Immunoprecipitated proteins were analyzed for PDE6 activity and by Western blotting with MOE antibody. The PDE6 activity immunoprecipitated from control retinas was $12-fold greater than that from Nrl À/À retinas and $7-fold greater than that from atrd3 retinas. All PDE6 enzymes in Nrl À/À retinas are predicted to be functional. Thus, the low-level immunoprecipitation of PDE6 activity from Nrl À/À retinas is consistent with the reported presence of up to 10% of rod PDE6 in Nrl À/À retina (Kolandaivelu, Chang, & Ramamurthy, 2011) . This also indicates the specificity of rod PDE6 precipitation by PDE6B PA1-722 antibody. In agreement with the immunoprecipitation levels of PDE6 activity, the immunoblot analysis with MOE antibody showed robust PDE6 signal in control IP samples, a very faint band in the atrd3 IP samples, and no detectable signal in the Nrl À/À IP samples (Fig. 6 ). Although these IP experiments are not quantitative, they clearly suggest that functional rod PDE6 represents only a fraction of total PDE6 activity in the atrd3 +/+ retina with the remaining activity apparently originating from cone PDE6.
Transgenic X. laevis model of atrd3 mutant counterpart of cone PDE6C
The N610S mutation (human PDE6C counterpart of N605S in mouse PDE6B) was introduced by PCR-directed mutagenesis into the PDE6C DNA sequence which was then cloned into the pXOP(À508/+41)EGFP vector. Transgenic X. laevis expressing EGFP-PDE6C-N610S have been generated by the method of sperm nuclear transplantation and characterized similarly as previously described for EGFP-PDE6C (Muradov, Boyd, & Artemyev, 2010; Muradov et al., 2009 ). The EGFP-fluorescence imaging in living photoreceptor cells showed that EGFP-PDE6C-N610S is expressed and properly localized to the rod OS in transgenic X. laevis (Fig. 7A) . The striated pattern of PDE6C-N610S EGFP-fluorescence is similar to the previously described pattern of EGFP-PDE6C ). This pattern is consistent with association of PDE6C-N610S with the rims and incisures of photoreceptor disks. The immunoblot analysis of the retinal extracts with anti-GFP antibody indicated that the average levels of EGFP-PDE6C-N610S expression are comparable to the levels of EGFP-PDE6C and well below the endogenous frog PDE6 (Fig. 7B). 3.4. Defective PDE6B pre-mRNA processing in atrd3 retina Transgenic X. laevis were generated using PDE6C cDNA construct, and therefore EGFP-PDE6C expression in the frog model does not depend on pre-mRNA processing. The contrast between markedly reduced levels of PDE6 in atrd3 mice and unimpaired expression of PDE6C-N610S in transgenic X. laevis prompted us to examine PDE6B mRNA sequence in mutant mice. RT-PCR amplification of the PDE6B region corresponding to nucleotides 794-1886 from atrd3 mRNA yielded the product that was $100-bp shorter than those from WT mRNA (Fig. 8A) . Sequencing of the product revealed deletion of exon 14 (nt 1722-1832) from the transcript (Fig. 8B) . This deletion introduces a frame shift and a premature stop codon downstream of exon 13 (Fig. 8B) . Consistent +/+ retinas. Retina cryosections of control and atrd3 +/+ were labeled with the PDE6B-specific antibody PA1-722 followed by staining with goat anti-rabbit AlexaFluor 488 secondary antibody. Fig. 6 . Immunoprecipitation of PDE6 from WT, Nrl À/À and atrd3 +/+ retinas with PDE6B-specific antibodies. Immunoprecipitations were carried out using hypotonic retina extracts and Protein G dynabeads with pre-bound anti-PDE6B PA1-722 antibodies. The inputs into IP experiments were equalized by the levels of trypsinactivated PDE6 activity. Aliquots of re-suspended beads with immunoprecipitated proteins were treated with trypsin and analyzed for PDE6 activity (A). Remaining aliquots were analyzed by immunoblotting with anti-PDE6 MOE antibody (B). with the exon 14 skipping, RT-PCR of atrd3 RNA designed to amplify nucleotides 1622-2606 of the PDE6B transcript also yielded shorter product as well as additional larger than predicted products (Fig. 8A) . The latter products are likely to contain additional intronic sequences downstream of exon 14. In order to determine if the defective splicing of the PDE6B mRNA is caused by a secondsite mutation, we sequenced a region of genomic DNA from atrd3 mice covering exons 13-15 and flanking introns. No additional mutations were found. Real-time PCR analysis indicated that exon 14 is missing in $80% of PDE6B transcripts in atrd3 retina. We further analyzed the atrd3 PDE6B transcripts containing exon 14 by PCR with 5 0 primer from exon 14 and 3 0 -primer from the 3 0 -UTR, which produced four discrete products. Sequencing indicated that one of these products represented correctly spliced PDE6B mRNA, whereas the remaining products contained one or more introns after exons 14, 15, 17, and 18 (not shown). Thus, we estimated that the fraction of the correctly spliced PDE6B mRNA in atrd3 retina is less than 5%.
Discussion
Mouse models with mutant rod PDE6 characterized to date present stark limitations for PDE6 biochemical analyses. Most of the reported mutations are random rather than targeted mutations that correspond to disease alleles in humans. Almost all mouse models with homozygous mutations in PDE6A or PDE6B revealed dramatic reductions in the protein level and activity of rod PDE6 (Chang et al., 2007; Sakamoto et al., 2009) . The markedly reduced levels of PDE6AB make it very difficult to distinguish the residual mutant rod PDE6 activity from the activity of cone PDE6C. Furthermore, the potential influence of processes leading to retinal degeneration on the properties of mutant PDE6 cannot be ruled out. We embarked on characterization of PDE6 in atrd3 mice with the missense N605S mutation in PDE6B based on indications that this mutation may alter PDE6 function rather than grossly affect the folding and/or assembly of rod PDE6. The structure of the chimeric PDE5/PDE6 catalytic domain shows that the H-loop Asn residue, a counterpart of PDE6BAsn 605 , makes two important contacts, one intramolecular contact with the M-loop and one intermolecular contact with Pc (Barren et al., 2009 ). The intramolecular bond may influence folding of PDE6, whereas the intermolecular contact may be important for the PDE6-Pc interaction. In the mutant PDE6 molecule, the Ser side chain would be able to maintain either one of the interactions, but not both contacts simultaneously (Barren et al., 2009 ). However, the Asn ? Ser mutation did not affect the expression levels and catalytic properties of the chimeric PDE5/ PDE6 catalytic domain, and it only modestly reduced the inhibition of its activity by Pc (Barren et al., 2009) . Unexpectedly, the analysis of PDE6 in P10 atrd3 retina showed a severe reduction of PDE6B. PDE6B is not detected by PDE6B-specific antibody using immunoblotting of atrd3 retina proteins or immunofluorescence analysis of retina sections. Interestingly, the levels of PDE6A in mutant retinas are comparable to those in control mice, suggesting that PDE6A is expressed in the absence of PDE6B. Nonetheless, PDE6A in atrd3 retinas is apparently catalytically inactive, since the overall PDE6 activity in the retina is reduced by $18-fold in comparison to control retinas. Similarly, nonfunctional PDE6A protein is expressed in the absence of PDE6B in rd1 retina (Tsang et al., 1996) . Immunoprecipitation of rod PDE6 from atrd3 retina extracts indicated that rod PDE6 activity constitutes only a fraction of the total PDE6 activity in mutant mice. Thus, prior to the onset of retinal degeneration, the degree of downregulation of rod PDE6 in atrd3 mice is likely to be significantly greater than 18-fold. The rate of retinal degeneration in atrd3 mice is slower than that in rd1 or Aipl1 À/À mice which have no functional rod PDE6 at any point of postnatal development (Lee et al., 1988; Ramamurthy et al., 2004; Tsang et al., 1996) . The time course of rod cell death in atrd3 mice appears to be slightly faster compared to the progression of retinal degeneration in rd10 mice with the R560C mutation in PDE6B or PDE6A mutant mice with the D670G substitution (Chang et al., 2007; Sakamoto et al., 2009 ). Both of these mouse models show significant reductions in PDE6 protein levels and/or activity (Chang et al., 2007; Sakamoto et al., 2009 ). Thus, a correlation apparently exists between the levels of functional PDE6 protein and the severity of retinal degeneration. Given the limitations of mouse models, new approaches to analysis of pathogenic PDE6 mutants are necessary. Recently, we demonstrated the utility of transgenic X. laevis for expression and characterization of recombinant PDE6C in rods (Muradov, Boyd, & Artemyev, 2010; Muradov et al., 2009) . The transgenic frog system offers several advantages. It allows imaging of EGFP-PDE6C expression and localization in living rods. Also, the potential influence of processes leading to retinal degeneration in homozygous mutant PDE6 mice can be avoided in the Xenopus model due to the presence of native frog rod PDE6. Finally, if a functional mutant rod PDE6AB is present in a mouse model, it is difficult to ascertain the activity of the mutant catalytic subunit in a heterodimer with the wild-type catalytic subunit. The X. laevis model of artd3 mutation yielded a very different phenotype. The PDE6C-N610S mutant was correctly targeted to the rod OS in the retina of transgenic X. laevis and apparently concentrated at the rims and incisures of photoreceptor disks, just as PDE6C. The average levels of protein expression of PDE6C-N610S were similar to those of PDE6C. Hypothetically, molecular differences between rod and cone PDE6 could have accounted for the differences in the phenotypes of the mouse and frog models. However, the site of atrd3 mutation, the H-loop of PDE6, is highly conserved among cone and rod PDE6 catalytic subunits, arguing against such a possibility. Transgenic EGFP-PDE6C expression in the frog model does not involve pre-mRNA processing. Therefore, we sequenced and analyzed PDE6B mRNA from P10 atrd3 retinas. This analysis demonstrated that $80% of the transcript lacked exon 14 carrying the N605S mutation. Furthermore, the predominant fraction of the remaining $20% transcript with exon 14 contained downstream intronic sequences. Thus, retinal degeneration in atrd3 mice is caused by defective processing of PDE6B mRNA and resulting very low levels of PDE6 protein rather than by effects of N605S mutation on the protein folding or stability.
Increasing evidence suggests that exonic missense and silent mutations can induce the splicing machinery to skip the mutant exon (reviewed in Cartegni, Chew, and Krainer (2002) ). About one quarter of synonymous variations in exon 12 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in exon skipping and inactive CFTR protein (Pagani, Raponi, & Baralle, 2005) . Exonic mutations may affect exonic splicing enhancers (ESEs) that have been recognized in many exons (Cartegni, Chew, & Krainer, 2002) . ESEs serve as binding sites for serine/arginine-rich (SR) protein splicing factors. For instance, a predicted ESE disruption by a single silent mutation in the survival of motor neuron 1 gene leads to the skipping of exon 7 and causes spinal muscular atrophy Lorson, Hahnen, Androphy, & Wirth, 1999) ; Analysis of the mouse PDE6B exon 14 sequence using ESEfinder 3.0 software (Smith et al., 2006) reveals the presence of several sites for SR proteins SF2/ASF and SC35. The Asn(AAC) ? Ser(AGC) mutation creates an additional SC35 site. The mechanism for skipping PDE6B exon 14 in atrd3 mice remains to be investigated. However, in a patient with growth hormone deficiency type II, mutation in ESE creates a functional SC35-binding site that synergistically with the downstream SC35 site produced pathological levels of exon 3 skipping. The effect of the additional SC35 site was due to SC35 antagonistic action with SF2/ASF (Solis et al., 2008) . A significant number of DNA polymorphisms were found in the PDE6B gene in RP patients, although no cosegregation analysis was performed (McLaughlin et al., 1995) . The atrd3 model highlights for the first time the possibility that missense mutations or SNPs in PDE6 genes can cause RP by aberrant splicing of pre-mRNA.
